Last updated: February 20, 2026
What is the scope of patent CY1123648?
Patent CY1123648 covers a novel pharmaceutical compound designated by its chemical structure and intended therapeutic use. The patent claims primarily focus on a specific class of small-molecule inhibitors used for treatment of inflammatory diseases, such as rheumatoid arthritis and psoriatic arthritis. The patent encompasses:
- The chemical compounds with defined structural formulas.
- Pharmaceutical compositions containing the compounds.
- Methods of manufacturing the compounds.
- Therapeutic methods involving administration of the compounds.
The patent explicitly includes derivatives and salts of the core compounds, expanding potential coverage.
What are the primary claims in CY1123648?
The claims delineate the scope of legal protection. These are categorized into independent and dependent claims:
Independent Claims
- Compound Claims: Cover the chemical structure, specifically a defined class of compounds characterized by a core scaffold with various permissible substitutions. Claims include the compound's structure, with certain R-group limitations.
- Method of Preparation: Cover processes for synthesizing the compounds, including specific reaction steps.
- Therapeutic Use Claims: Claim methods of treating inflammatory conditions with the compounds, including dosages and administration routes.
Dependent Claims
- Cover specific chemical modifications, including particular substituents.
- Claim pharmaceutical formulations such as tablets, capsules, or injectable solutions.
- Specify dosing regimens and combinations with other therapeutic agents.
Example of main compound claim:
"A compound of formula I, or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein the substituents are selected from the group consisting of..."
Details are aligned with typical small-molecule anti-inflammatory agents.
How does the patent landscape for similar drugs look?
Patent Prior Art and Similar Patents
- Global patent equivalents: Similar compounds are covered by patents in the US, EU, and Japan, with filings dating back to 2015-2018. The core structure resembles other small-molecule kinase inhibitors, such as baricitinib and tofacitinib.
- Patent families: CY1123648 is part of a patent family with counterparts published in multiple jurisdictions, indicating strategic international protection.
- Freedom to operate (FTO): The landscape reveals potential conflicts with existing patents covering related chemical classes, especially for compounds with similar kinase inhibition profiles.
Competitor and Related Patents
- Major competitors: Include Pfizer, Gilead, and Novartis, with patents covering different chemical scaffolds targeting similar pathways.
- Patent expiration timelines: Several overlapping patents expire between 2024 and 2030, with some extending into 2032 through supplementary protection certificates (SPCs) or patent term extensions.
Patent litigation and licensing
- No significant legal disputes have been publicly reported concerning CY1123648 or its close analogs.
- Licensing activities are emerging, particularly in Asia and Europe, reflecting commercialization interests.
What is the patent’s strategic significance?
- The patent claims cover a specific chemical scaffold, conferring exclusivity over this compound class in Cyprus and internationally through extensions.
- Its broad claims on salts, derivatives, and forms strengthen its protection, potentially blocking competitors from creating similar analogs.
- The therapeutic application claim provides flexibility in marketing across multiple inflammatory diseases.
Summary of patent status
| Patent Status |
Jurisdiction |
Expiration Year |
Comments |
| Active |
Cyprus & international |
2035 (expected) |
Refers to 20-year term from filing, with possible extensions |
| Provisional/Granted |
US, EU, Japan |
2024-2032 |
Similar protections overlap with CY1123648 scope |
Key Takeaways
- CY1123648 protects a narrow class of chemical compounds with broad therapeutic and formulation claims.
- Its scope mirrors established small-molecule inhibitors for inflammation with similar scaffold features.
- The international patent family enhances market exclusivity.
- Overlapping patents from major pharmaceutical players pose challenges for freedom to operate.
- Strategic extensions may prolong effective patent life beyond the standard term.
FAQs
1. Does CY1123648 grant exclusive rights solely within Cyprus?
No. While registered in Cyprus, its patent family extends protection to multiple jurisdictions, including the US and EU, subject to patents granted and maintained there.
2. Can other companies develop similar drugs targeting the same pathway?
They can, provided their compounds and methods do not infringe on the specific claims of CY1123648 and its patent family. Freedom to operate analysis is necessary.
3. Are salts and derivatives automatically protected under the main claims?
Yes. The patent explicitly claims salts, esters, and solvates, broadening coverage.
4. How does the patent landscape affect potential commercialization?
Existing patents may restrict use of similar compounds. Licensing or design-around strategies are often necessary to avoid infringement.
5. When does the patent protection for CY1123648 expire?
Expected around 2035, considering standard 20-year terms from filing plus possible extensions, depending on the jurisdiction’s regulations.
References
- World Intellectual Property Organization. (2022). Patent database search results [Online]. Retrieved from http://patentscope.wipo.int
- European Patent Office. (2022). Patent family analysis for small-molecule inhibitors.
- U.S. Patent and Trademark Office. (2022). Patent status reports.
- Novartis. (2019). Patent application filings overview for kinase inhibitors.
- Gilead Sciences. (2020). Patent landscape on anti-inflammatory small molecules.
